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The  circulating  soluble  tumor  necrosis  factor  (sTNF)  and  sTNF-receptor  (R)  1  and  -R2
have  known  as septic  biomarker.  The  pungent  component  of capsicum,  capsaicin  (Cap),
has several  associated  physiological  activities,  including  anti-oxidant,  anti-bacterial  and
anti-inﬂammatory  effects.  The  aim  of  this  study  was  to elucidate  the effect  of Cap  on  cir-
culating  sTNF and  sTNF-R1  and -R2  in  vivo  using  lipopolysaccharide  (LPS)-treated  mice.
LPS (20  mg/kg,  ip)-treated  group  was  signiﬁcantly  increased  circulating  sTNF,  sTNF-R1,  and
-R2 and  TNF-  mRNA  expression  levels compared  to the vehicle  group.  Treatment  with  LPS
(20  mg/kg,  ip)  +  Cap  (4 mg/kg,  sc)-treated  group  was  signiﬁcantly  decreased  both  circulating
sTNF  levels  (after 1 h only)  and TNF-  mRNA  expression  (after  6 h) compared  to the  LPS-
treated  group.  There  is an early  increase  in  circulating  sTNF,  sTNR-R1,  and  -R2  observed  in
the  LPS-treated  mice.  Since  Cap  inhibits  this  initial  increase  as  biomarkers,  circulating  sTNF,and 2 (TNF-R 1 and 2)
TNF-converting  enzyme (TACE)
it is  considered  a  potent  treatment  option  for TNF--related  diseases,  such  as  septicemia.
In  conclusion,  Cap  interferes  with  TNF-  mRNA  transcription  and  exerts  an  inhibiting  effect
on TNF-  release  from  macrophages  in  the  early  phase  after  LPS  stimulation.  Thus, Cap  is
considered  a potent  agent  for  the  treatment  of  TNF--related  diseases,  such  as septicemia.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. IntroductionThe pungent component of capsicum, capsaicin (Cap),
has  several associated physiological activities, including
Abbreviations: Cap, capsaicin; LPS, lipopolysaccharide; NO, nitric
oxide; PBS, phosphate buffered saline; TACE, TNF-converting enzyme;
TNF-, tumor necrosis factor-alpha; TNF-R, tumor necrosis factor-
receptor.
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anti-oxidant, anti-bacterial and anti-inﬂammatory effects
[1–3].
LPS  is an outer membrane component of Gram-negative
bacteria and has been reported to activate NF-B  via
toll-like receptor 4 (TLR4), which is present on antigen-
presenting cells such as dendritic cells or macrophages [4],
releasing  pro-inﬂammatory mediators, including TNF-,
interleukins (IL-1, IL-6, IL-10) [5,6], and nitric oxide (NO)
[7].  Macrophages can also release TNF- (as soluble TNF
[sTNF]) [8], which mediates its biological activities through
binding to type 1 and 2 TNF receptors (TNF-R1 and -R2)
 access article under the CC BY-NC-ND license
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9,10]. In addition, TNF-R2, the principal mediator of the
ffects  of TNF- on cellular immunity, may  cooperate with
NF-R1  in the killing of nonlymphoid cells [11]. When TNF-
1  and/or -R2 are stimulated by TNF-, the extracellular
ortions of transmembrane proteins are cleaved, soluble
ctodomains are released from the cell surface by a shed-
ase  known as TNF-converting enzyme (TACE) [12], and
TNF  is neutralized by the sTNF-Rs [13]. After cell stim-
lation by various stimuli, including TNF- itself, these
wo  receptors can be proteolytically cleaved by TACE [14]
nto  two soluble forms, sTNF-R1 and sTNF-R2, which show
rolonged elevation in the circulation of patients with var-
ous  inﬂammatory diseases such as septicemia, leukemia,
epatitis C virus infection, lupus, rheumatoid arthritis, and
ongestive  heart failure [15–22]. Furthermore, increased
irculating levels of sTNF-R1 and -2 have been reported in
 rat model of CCL4 induced-liver injury [23].
The aim of this study was to investigate the effect of
ap  on circulating TNF- (sTNF), sTNF-R1, and -R2 levels
n  LPS-treated mice. The expression of TNF-, sTNF-R1 and
R2  proteins and mRNA were also examined in blood at
ifferent  time points.
.  Materials and methods
.1.  Materials
LPS (Escherichia coli, 055:B55, Lot No. 114K4107) was
urchased from Sigma–Aldrich, Co. (MO, USA), and Cap
98%  purity) was provided by Maruishi Pharmaceutical Co.,
td.  (Osaka, Japan). Other reagents used were commercially
vailable extra-pure grade chemicals.
.2. Animals
Male BALB/c mice (age, 8–10 weeks; weight, 21–26 g;
apan SLC, Inc., Shizuoka, Japan) were used. They were
oused for at least one week under controlled environmen-
al conditions (temperature, 24 ± 1 ◦C; humidity, 55 ± 10%;
ight  cycle, 6:00–18:00) with free access to solid food
NMF, Oriental yeast Co., Ltd., Tokyo, Japan) and water. All
xperimental procedures were conducted according to the
uidelines  for the use of experimental animals and animal
acilities established by Osaka University of Pharmaceutical
ciences.
.3. Treatment of mice
LPS  was dissolved in 2 mg/ml  of physiological saline
Fuso Pharmaceutical Industries Ltd., Osaka, Japan) and
iluted  to 1 mg/ml  in physiological saline. Cap was dis-
olved  in 1% ethanol + 1% Tween 20 in physiological saline.
PS  (20 mg/kg) was administered intraperitoneally (ip) and
 mg/kg Cap was administered subcutaneously (sc) to the
acks  of the mice 5 min  after LPS administration.
.4.  Measurement of circulating sTNF, sTNF-R1, and
TNF-R2 levels
Mice  were divided into four groups: vehicle group, LPS
roup,  Cap group, and LPS + Cap group. The animals weres 1 (2014) 1062–1067 1063
sacriﬁced under anesthesia for the following procedures
at 1, 3, 6, 9, and 12 h after LPS administration. Whole
blood was  taken from the abdominal aorta of the mice. The
samples  were centrifuged, and the supernatant was mea-
sured.  Measurements were performed using Quantikine®
Immunoassay Mouse TNF-, Quantikine® Immunoassay
Mouse sTNFRI, and Quantikine® Immunoassay Mouse
sTNFRII (R&D Systems, Inc., MN,  USA). Within 30 min,
absorbance was measured at 450 nm and 570 nm using a
plate  reader (Labsystems Multiscan MS;  Dainippon Sumit-
omo  Pharma Co. Ltd., Osaka, Japan). The measured value of
the  vehicle group was  deﬁned as the control value. The lim-
its  of detection of sTNF, sTNF-R1, and sTNF-R2 levels were
5.1,  5.0, and 5.0 pg/ml, respectively.
2.5. Measurement of circulating TNF-˛, TNF-R1, and
TNF-R2 mRNA expression (derived from macrophages)
levels in whole blood
Whole  blood was taken from the abdominal aorta of
the  mice under anesthesia at 0.5, 1, 3, 6, and 9 h after LPS
administration. Total RNA was extracted from 300 l of
whole  blood using a total RNA extraction kit (PureLinkTM
Total RNA Blood Puriﬁcation Kit for isolating total RNA
from  whole Blood; Invitrogen Corporation, CA, USA). Syn-
thesis  of cDNA was performed by reverse transcription
using total RNA solution (PrimeScriptTM RT reagent Kit;
Takara Bio Inc, Shiga, Japan), and mRNA was  measured
using a thermal cycler (LightCycler®, Roche Diagnostics,
Basel, Switzerland). The results were adjusted using glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) and 18s
rRNA,  a housekeeping gene, as the internal standards.
2.6. Data analysis
Values  are shown as mean ± standard deviation (SD).
Statistical analysis was  performed using Tukey’s test. A sig-
niﬁcant  difference was  determined as P < 0.05.
3. Results
3.1. Circulating sTNF, sTNF-R1, and sTNF-R2 levels
The circulating sTNF level signiﬁcantly increased in the
LPS  group 1 h after LPS administration compared to both
the  vehicle (P < 0.01, Fig. 1A) and LPS + Cap (P < 0.01, Fig. 1A)
groups  (n = 3–4). There was no signiﬁcant difference in the
circulating sTNF levels between the vehicle and LPS + Cap
groups  (Fig. 1A). From 3 h to 12 h after LPS stimulation, cir-
culating  sTNF levels in the LPS group signiﬁcantly increased
compared to the vehicle group (P < 0.05 or 0.01, Fig. 1A).
Both the circulating sTNF-R1 and -R2 levels in the LPS
and  LPS + CAP groups signiﬁcantly increased from 0.5 h
to  12 h after LPS administration, compared to the vehicle
group (P < 0.05 or 0.01, Fig. 1B and C). No such differences in
circulating  sTNF-R1 levels were observed between the LPS
group  and the LPS + Cap group (Fig. 1B and C). But at 0.5 h
after  LPS administration, sTNF-R1 levels in the LPS + Cap
group  were signiﬁcantly decreased, compared to the LPS
group  (P < 0.05, Fig. 1B).
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Fig. 1. The chronological changes in circulating soluble tumor necrosis factor (sTNF), sTNF-receptor 1 (R1), and sTNF-R2 levels. Mice were treated with or
without  lipopolysaccharide (LPS) 20 mg/kg, and were treated with LPS 20 mg/kg and capsaicin (Cap) 4 mg/kg. (A) Circulating sTNF level mice. Data shows
mean  ± SD (n = 3–4). (B) Circulating sTNF-R1 level in mice. Data shows mean ± SD (n = 3–4). (C) Circulating sTNF-R2 level in mice. Data shows mean ± SD
(n  = 3–4). *P < 0.05, compared to the vehicle group. **P < 0.01, compared to the vehicle group. †P < 0.05, ††P < 0.01, compared with LPS group.
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Fig. 2. The chronological changes in circulating tumor necrosis factor (TNF)-, TNF-receptor (TNF-R) 1 and TNF-R2 mRNA expression levels. Mice were
treated  with or without lipopolysaccharide (LPS) 20 mg/kg, and were treated with LPS 20 mg/kg and capsaicin (Cap) 4 mg/kg. (A) Circulating TNF- mRNA
expression  level in mice. Data shows mean ± SD (n = 3). (B) Circulating TNF-R1 mRNA expression level in mice. Data shows mean ± SD (n = 3). (C) Circulating
TNF-R1  mRNA expression level in mice. Data shows mean ± SD (n = 3). *P < 0.05, compared to the vehicle group (without LPS administration), **P < 0.01,
compared  to the vehicle group (without LPS administration), †P < 0.05, compared to the LPS group, ††P < 0.01, compared to the LPS group.
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At 9 h and 12 h after LPS administration, sTNF-R2 levels
in  the LPS + Cap group were signiﬁcantly decreased com-
pared  to the LPS group (P < 0.01, Fig. 1C).
3.2.  Expression of circulating TNF-˛, TNF-R1, and TNF-R2
mRNA derived from leucocytes
Compared  to the vehicle group, no signiﬁcant change
was observed in the circulating TNF-, TNF-R1, or TNF-
R2  mRNA expression levels in the Cap group (data not
shown). The circulating TNF- mRNA expression level in
the  LPS group was signiﬁcantly increased 0.5, 1, 3, 6, and
9  h after LPS administration (P < 0.05, Fig. 2A) compared
to the vehicle group. Despite this, the circulating TNF-
mRNA expression level in the LPS + Cap group signiﬁcantly
decreased 0.5, 1, 3, and 9 h after LPS administration com-
pared  to the vehicle group (P < 0.05, Fig. 2A).
The circulating TNF-R1 mRNA expression level in the
LPS  group signiﬁcantly decreased 0.5, 1, and 3 h after LPS
administration compared to the vehicle group (P < 0.05 or
0.01,  Fig. 2B), even though they were signiﬁcantly increased
6  h and 9 h after LPS administration compared to the vehi-
cle  group (P < 0.05, Fig. 2B). Furthermore, the circulating
TNF-R1 mRNA expression level in the LPS + Cap group sig-
niﬁcantly increased 9 h after LPS administration compared
with  the vehicle group (P < 0.05, Fig. 2B).
The circulating TNF-R2 mRNA expression level in the
LPS  group signiﬁcantly decreased 0.5 h after LPS adminis-
tration compared to the vehicle group (P < 0.05, Fig. 2C).
Despite this, the circulating TNF-R2 mRNA expression level
in  the LPS + Cap group signiﬁcantly increased 6 h after LPS
administration compared to the vehicle group (P < 0.01,
Fig.  2C).
4.  Discussion
Cap has been previously reported to improve the sur-
vival  rate of LPS-treated mice [24], although the precise
mechanism of the effect of Cap was not explained. The aim
of  this study was to elucidate the effect of Cap on circulating
biomarkers, sTNF, sTNF-R1, and -R2 levels in LPS-treated
mice.
Increased circulating sTNF-R1 and -R2 levels have been
reported in patients with hepatitis C virus infection [18],
and  increased circulating sTNF-R2 levels in patients with
congestive heart failure [17], obesity-impaired glucose
tolerance [25], and leukemia [20,22]. In this study, we  con-
ﬁrmed  that the circulating sTNF-R2 levels in plasma were
approximately 10-fold higher than the circulating sTNF-
R1  levels at each time point [23]. Since the circulating
sTNF, sTNF-R1, and -R2 levels are the initial signals of an
immune  response, plasma changes in them could represent
a  biomarker detectable at an earlier stage than C-reactive
proteins, leukocytes, and fever during sepsis or systemic
inﬂammatory response syndrome (SIRS). These values thus
are  known biomarkers of septic shock [15].
At the time to maximum plasma concentration (Tmax;
1  h after LPS administration), circulating sTNF level in LPS
group  was signiﬁcantly increased compared to these levels
in  vehicle or LPS + Cap groups. The level declined from 3 h to
12  h, but the level in the LPS group signiﬁcantly increaseds 1 (2014) 1062–1067
compared to the vehicle group (Fig. 2A). While the TNF-
mRNA  expression level derived from blood (including leu-
cocytes)  in the LPS group also signiﬁcantly increased from
0.5  h to 9 h compared with the vehicle or LPS + Cap groups
(Fig.  2A). This difference may  be due to the release of stored
membrane-bound TNF- (mTNF) from macrophages 1 h
after  LPS stimulation [26]. Following LPS stimulation (in
inﬂammation), TNF- is primarily expressed as a 26 kDa
type  II transmembrane protein, mTNF and is subsequently
cleaved by the metalloproteinase-disintegrin TNF- con-
verting  enzyme (TACE, also known as ADAM-17) into the
secreted  17 kDa monopeptide TNF- (sTNF) [12,14,27].
Similarly, TACE, a member of the ADAM family of zinc
metalloproteinases, modulates the generation of sTNF-
R1  and -R2 by proteolytically cleaving the TNF-R1 and
-R2  ectodomains, respectively [27]. Following a single LPS
stimulation, the circulating sTNF level in the LPS group
signiﬁcantly and continuously increased from 3 h to 12 h
compared  to the vehicle group. At 1 h after LPS stimu-
lation the circulating sTNF was  considered to be derived
from mTNF. From 3 h onwards after LPS stimulation, the
circulating sTNF level was  considered to be derived from
TNF-  mRNA induced by LPS. While both sTNF-R1 and -R2
mRNA  levels were not differences among vehicle, LPS, and
LPS  + Cap groups from 0.5 h to 12 h after LPS stimulation.
Furthermore, the circulating sTNF-R2 level was approxi-
mately 10-fold that of sTNF-R1 in this study, similar to these
levels  of carbon tetrachloride-induced liver injury rats [23].
TNF-R1  has been reported to bind to sTNF more frequently
than TNF-R2 [26]; therefore, we assumed that binding with
TNF-  after LPS stimulation neutralized TNF-R1, resulting
in  decreased circulation of both sTNF and sTNF-R1.
Regarding the effects of Cap on sTNF, the sTNF level in
the  LPS + Cap group was signiﬁcantly depressed by Cap 1 h
after  LPS stimulation compared to the LPS group (Fig. 1A).
Cap,  therefore, has the potential to depress the production
of  sTNF via membrane stability. Furthermore, Cap signiﬁ-
cantly  depressed TNF- mRNA from 0.5 h to 9 h (Fig. 2A).
Cap  was assumed to depress the increase in TNF- mRNA
in  LPS-treated mice. The above-mentioned results show
that  Cap has the potential to suppress TNF- production
following LPS-stimulation [28,29].
Our results assume the following two  mechanisms for
the  anti-TNF- effect of Cap: ﬁrstly, Cap exerts a release-
inhibiting effect on circulating sTNF from macrophages
in the early phase of septicemia; secondly, Cap interferes
with TNF- mRNA transcription. Since Cap inhibits the ini-
tial  increase in circulating sTNF, it is considered a potent
treatment option for TNF--related diseases, such as sep-
ticemia.
5.  Conclusion
There is an early increase in circulating sTNF, sTNR-R1,
and -R2 observed in the LPS-treated mice. Cap interferes
with TNF- mRNA transcription and exerts an inhibiting
effect on TNF- release from macrophages in the early
phase after LPS stimulation. Thus, Cap is considered a
potent  agent for the treatment of TNF--related diseases,
such as septicemia.
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